2. Search Result
Search Result
Results for "

HK-2

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Fluorescent Dye

3

Peptides

8

Natural
Products

2

Recombinant Proteins

6

Antibodies

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155008
    PROTAC HK2 Degrader-1
    2 Publications Verification

    		 PROTACs Hexokinase Cancer
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .
    PROTAC HK2 Degrader-1
  • HY-156277
    SP4f

    		PPAR Metabolic Disease
    SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4f
  • HY-156276
    SP4e

    		PPAR Metabolic Disease
    SP4e is an activator of PPAR-γ, with the EC50 of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4e
  • HY-130437
    p-nitro-Pifithrin-α

    		MDM-2/p53 TGF-β Receptor Caspase Infection Metabolic Disease
    p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease [2] .
    p-nitro-Pifithrin-α
  • HY-RS06193
    HK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HK2 Human Pre-designed siRNA Set A contains three designed siRNAs for HK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HK2 Human Pre-designed siRNA Set A
    HK2 Human Pre-designed siRNA Set A
  • HY-RS16576
    Hk2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hk2 Mouse Pre-designed siRNA Set A
    Hk2 Mouse Pre-designed siRNA Set A
  • HY-RS23009
    Hk2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Hk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Hk2 Rat Pre-designed siRNA Set A
    Hk2 Rat Pre-designed siRNA Set A
  • HY-175035
    HK-2-IN-1

    		Hexokinase Inflammation/Immunology Cancer
    HK-2-IN-1 is a Hexokinase 2 (HK-2) inhibitor. HK-2-IN-1 exhibits a non-activating effect on human recombinant HK-2 enzyme. HK-2-IN-1 has anti-tumor activity, affecting immune cells in the tumor microenvironment. HK-2-IN-1 has immunomodulatory effects and is potentially useful in the study of cancers such as colon cancer, liver cancer, and breast cancer .
    HK-2-IN-1
  • HY-168717
    HK-2-IN-2

    		Hexokinase Microtubule/Tubulin Reactive Oxygen Species (ROS) Cancer
    HK2-IN-2 (Compound 26) is a Hexokinase 2 inhibitor that demonstrates significant anti-tumor activity by targeting microtubules and Hexokinase 2, with an IC50 value of 0.764 μM against MD-MBA-231 cells. HK2-IN-2 effectively inhibits the activity of Hexokinase 2, leading to the accumulation of Reactive Oxygen Species and dysfunction of the mitochondrial membrane potential (MMP), thereby promoting apoptosis and blocking the cell cycle .
    HK-2-IN-2
  • HY-156368
    RIPK3-IN-4

    		RIP kinase Inflammation/Immunology
    RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury .
    RIPK3-IN-4
  • HY-125938
    Cycloartenyl ferulate
    1 Publications Verification

    Cycloartenol ferulate; Cycloartenol ferulic acid ester

    		 Drug Derivative Apoptosis Reactive Oxygen Species (ROS) JAK STAT Inflammation/Immunology Cancer
    Cycloartenyl ferulate (Cycloartenol ferulate; Cycloartenol ferulic acid ester) is a derivative of γ-oryzanol (HY-B2194) with multiple biological activities including antioxidant, anti-inflammatory, and anti-tumor properties. Cycloartenyl ferulate selectively binds to IFNγR1 (binding affinity Kd = 0.5 μM) to activate the canonical JAK1/2-STAT1 signaling pathway. Cycloartenyl ferulate inhibits paraquat (PQ)-triggered apoptosis and ROS in HK2 cells. Cycloartenyl ferulate enhances the activation and cytolytic activity of natural killer (NK) cells by upregulating the expression of NK cell activation receptors (NKG2D, NKp30, NKp44) and the release of cytotoxic molecules and cytokine IFNγ. Cycloartenyl ferulate exerts anti-cancer effects in tumor mice models. Cycloartenyl ferulate can be used for the study of cancer and allergic inflammation intervention [2] .
    Cycloartenyl ferulate
  • HY-RS06288
    HOOK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    HOOK2 Human Pre-designed siRNA Set A contains three designed siRNAs for HOOK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HOOK2 Human Pre-designed siRNA Set A
    HOOK2 Human Pre-designed siRNA Set A
  • HY-RS07380
    KLK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for KLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KLK2 Human Pre-designed siRNA Set A
    KLK2 Human Pre-designed siRNA Set A
  • HY-RS07282
    KIF2A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KIF2A Human Pre-designed siRNA Set A contains three designed siRNAs for KIF2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KIF2A Human Pre-designed siRNA Set A
    KIF2A Human Pre-designed siRNA Set A
  • HY-126710
    OU749

    		γ-Glutamyl Transferase (GGT) Cancer
    OU749 is a potent γ-glutamyl transpeptidase (GGT) inhibitor with a Ki value of 17.6 µM. OU749 shows cytotoxicity .
    OU749
  • HY-173024
    TRPC4/5-IN-3

    		TRP Channel Neurological Disease
    TRPC4/5-IN-3 (Compound 32) is the orally active inhibitor for transient receptor potential canonical channel 4/5 (TRPC4/5) with IC50 of 3.6 nM and 5.5 nM. TRPC4/5-IN-3 inhibits hERG channel with IC50 of 6.5 µM. TRPC4/5-IN-3 exhibits good metabolic stability in human/rat/mouse liver microsomes. TRPC4/5-IN-3 exhibits antidepressant and anxiolytic activity in mouse models, exhibits good pharmacokinetic characteristics in mouse with an oral bioavailability of 87% .
    TRPC4/5-IN-3
  • HY-123409
    Nicousamide

    		TGF-β Receptor Metabolic Disease
    Nicousamide is a potent inhibitor of TGF-β RII phosphorylation. Nicousamide can be used to study renal fibrosis in animal models of diabetic nephropathy .
    Nicousamide
  • HY-RS07101
    KCNA5 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KCNA5 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KCNA5 Human Pre-designed siRNA Set A
    KCNA5 Human Pre-designed siRNA Set A
  • HY-172400
    FXIa-IN-16

    		Factor XI Cardiovascular Disease
    FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis .
    FXIa-IN-16
  • HY-N0401B
    (E)-Ligustilide

    		Others Metabolic Disease
    (E)-Ligustilide is isolated from Angelica?sinensis and has nephroprotective?effects .
    (E)-Ligustilide
  • HY-120371
    CPUY192018
    1 Publications Verification

    		 Keap1-Nrf2 Apoptosis Reactive Oxygen Species (ROS) NF-κB Inflammation/Immunology
    CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, with an IC50 of 0.63 µM. CPUY192018 exhibits anti-inflammatory and antioxidant activities. CPUY192018 can activate the Nrf2-dependent antioxidant pathway and inhibit the NF-κB-related inflammatory response. CPUY192018 can be used in the research of inflammation-related diseases [2].
    CPUY192018
  • HY-N2013
    Aristolactam I
    1 Publications Verification

    Aristololactam; Aristolactam

    		 Drug Metabolite Aquaporin Cadherin TGF-beta/Smad Endocrinology Cancer
    Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis [2] .
    Aristolactam I
  • HY-W017018
    L-Ornithine hydrochloride
    Maximum Cited Publications
    8 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    L-Ornithine hydrochloride is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine hydrochloride shows nephroprotective [2].
    L-Ornithine hydrochloride
  • HY-176236
    Lipophagy inducer 1

    		LXR Autophagy Metabolic Disease
    Lipophagy inducer 1 (Compound 2726.007) is a lipophagy inducer. Lipophagy inducer 1 has the primary activity of reducing lipid droplet accumulation and rescuing podocyte cell death. Lipophagy inducer 1 exerts its effects by activating lipophagy and regulating the LXR signaling pathway. Lipophagy inducer 1 can be used in the study of the treatment of diabetic nephropathy (DKD) and other diseases related to lipid metabolism disorders .
    Lipophagy inducer 1
  • HY-155751
    HMGB1-IN-1

    		Interleukin Related TNF Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    HMGB1-IN-1 (compound 6) displays strong NO inhibitory effect in RAW264.7 cells with IC50 value of 15.9 ± 0.6 μM. HMGB1-IN-1 inhibit the HMGB1/NF-κB/NLRP3 pathway. HMGB1-IN-1 shows good anti-inflammatory activity and good anti-sepsis effects in kidney injury .
    HMGB1-IN-1
  • HY-122615B
    SPOP-IN-6b dihydrochloride
    2 Publications Verification

    		 E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b dihydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b dihydrochloride
  • HY-146560
    Xanthine oxidase-IN-6

    		Xanthine Oxidase NF-κB Toll-like Receptor (TLR) TNF Receptor Metabolic Disease Inflammation/Immunology
    Xanthine oxidase-IN-6 (Compound 6c) is a potent, orally active, mixed-type xanthine oxidase (XOD) inhibitor with an IC50 value of 1.37 µM. Xanthine oxidase-IN-6 shows strong anti-hyperuricemia and renal protective activity .
    Xanthine oxidase-IN-6
  • HY-W017018R
    L-Ornithine hydrochloride (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    L-Ornithine (hydrochloride) (Standard) is the analytical standard of L-Ornithine (hydrochloride). This product is intended for research and analytical applications. L-Ornithine hydrochloride is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine hydrochloride shows nephroprotective [2].
    L-Ornithine hydrochloride (Standard)
  • HY-122615A
    SPOP-IN-6b hydrochloride

    		E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b hydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b hydrochloride
  • HY-B1352
    L-Ornithine
    Maximum Cited Publications
    8 Publications Verification

    (S)-2,5-Diaminopentanoic acid

    		 Arginase Endogenous Metabolite Metabolic Disease
    L-Ornithine ((S)-2,5-Diaminopentanoic acid) is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine shows nephroprotective [2].
    L-Ornithine
  • HY-172600
    TRPC6 antagonist-1

    		TRP Channel Inflammation/Immunology
    TRPC6 antagonist-1 (X26) is a TRPC6 antagonist with IC50 values of 0.97 μM, 3.93 μM, 5.77 μM and 4.37 μM for TRPC6, TRPC3, TRPC5 and TRPC7, respectively. TRPC6 antagonist-1 inhibits TGF-β1-induced myofibroblast differentiation, and attenuates renal fibrosis .
    TRPC6 antagonist-1
  • HY-173414
    PROTAC STING degrader-3

    		PROTACs STING NF-κB Inflammation/Immunology
    PROTAC STING degrader-3 (Compound ST9) is a STING PROTAC degrader (DC50: 0.62 μM). PROTAC STING degrader-3 induces STING degradation via the ubiquitin-proteasome pathway. PROTAC STING degrader-3 exerts anti-inflammatory effects by inhibiting STING/TBK1/NF-κB signaling. PROTAC STING degrader-3 has renal protective effects and can be used in the study of acute kidney injury (AKI) (Pink: STING ligand (HY-47709); Blue: E3 ligase CRBN ligand (HY-41547); Black: linker) .
    PROTAC STING degrader-3
  • HY-110021
    Fenoldopam hydrochloride

    SKF 82526 hydrochloride

    		 Dopamine Receptor Histone Demethylase Apoptosis Cardiovascular Disease Cancer
    Fenoldopam (SKF 82526) hydrochloride is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam hydrochloride shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis [2] .
    Fenoldopam hydrochloride
  • HY-151544
    PNE-Lyso

    		Fluorescent Dye Others
    PNE-Lyso is a activatable fluorescent probe. PNE-Lyso can be used to detect intracellular pH and hexosaminidases with two kinds of fluorescence signals. PNE-Lyso can be used to distinguish apoptosis from necrosis through visualizing lysosome morphology. PNE-Lyso is capable of investigating the agent-induced cell death process .
    PNE-Lyso
  • HY-149053
    OY-101

    		P-glycoprotein Cancer
    OY-101 is an orally active, potent and specific P-glycoprotein (P-gp) inhibitor. OY-101 can sensitize drug-resistant tumors and effectively reverse tumor multidrug resistance. OY-101 is improvements in water-solubility, cytotoxicity, and reversal activity compared to Tetrandrine (HY-13764) .
    OY-101
  • HY-163748
    GSK-3β inhibitor 17

    		GSK-3 Inflammation/Immunology
    GSK-3β inhibitor 17 (compound 5 n) is a potent GSK-3β inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury .
    GSK-3β inhibitor 17
  • HY-161852
    PI3K-IN-55

    		PI3K Apoptosis Cancer
    PI3K-IN-55 (Compound 6a) is a potent inhibitor for PI3K. PI3K-IN-55 affects PI3K/Akt/p53 signaling pathway, inhibits the proliferation of cancer cells A549, Hela, HepG2, MCF-7 and HT-29, with IC50s of 1.03-6.78 μM. PI3K-IN-55 induces apoptosis in cell MCF-7 .
    PI3K-IN-55
  • HY-162584
    TRPC5-IN-6

    		TRP Channel Others
    TRPC5-IN-6 (Compound 12) is an orally effective transient receptor potential (TRPC5) inhibitor with a IC50 value of 81 nM. TRPC5-IN-6 has good biosafety and low liver and kidney toxicity, and is expected to play an important role in the treatment of chronic kidney disease (CKD) .
    TRPC5-IN-6
  • HY-P2813
    Hirudin
    3 Publications Verification

    		 Thrombin Apoptosis Cardiovascular Disease Cancer
    Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
    Hirudin
  • HY-P5314
    OK2

    		EGFR STAT Others
    OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .
    OK2
  • HY-B0735A
    Fenoldopam mesylate
    4 Publications Verification

    Fenoldopam methanesulfonate; SKF-82526 mesylate

    		 Dopamine Receptor Apoptosis Cardiovascular Disease Cancer
    Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis [2] .
    Fenoldopam mesylate
  • HY-B0735AR
    Fenoldopam mesylate (Standard)

    Fenoldopam methanesulfonate (Standard); SKF-82526 mesylate (Standard)

    		 Reference Standards Dopamine Receptor Apoptosis Cardiovascular Disease Cancer
    Fenoldopam (mesylate) (Standard) is the analytical standard of Fenoldopam (mesylate). This product is intended for research and analytical applications. Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis [2] .
    Fenoldopam mesylate (Standard)
  • HY-133541
    Glucopiericidin A

    		GLUT ADC Payload Apoptosis Cancer
    Glucopiericidin A is a natural piericidin compound obtained from a marine-derived Streptomyces strain. Glucopiericidin A serves as a glucose transporter (GLUT) chemical probe and suppresses glycolysis. Glucopiericidin A inhibits ATP-dependent filopodia protrusion with Piericidin A (PA; HY-114936) and has no effect alone. Glucopiericidin A induces cell apoptosis through reducing the reactive oxygen species (ROS) level by increasing PRDX1 and exhibits potent antitumor efficacy in ACHN mice xenografts [2].
    Glucopiericidin A
  • HY-W002942
    Ferroptosis-IN-21

    1,2,3,4-Tetrahydroquinolin-8-ol; 8-hydroxy-1,2,3,4-tetrahydroquinoline

    		 Ferroptosis Reactive Oxygen Species (ROS) Inflammation/Immunology
    Ferroptosis-IN-21 is a ferroptosis inhibitor that protects against renal I/R injury by suppressing ferroptosis and directly scavenging peroxyl radicals. Ferroptosis-IN-21 displays broad-spectrum anti-ferroptotic efficacy across multiple inducers in renal tubular epithelial cells, with nanomolar potency and robust suppression of lipid Reactive Oxygen Species (ROS). Ferroptosis-IN-21 significantly ameliorates renal I/R injury in mice, reducing histological damage, functional impairment, and inflammatory cytokine expression, while decreasing lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-12 can be used for research in the field of ferroptosis-targeted drug development .
    Ferroptosis-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: